SidaSubSaharaV1, Main, Exploration, bibRecord, 000C25

A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.

Identifieur interne : 000C25 ( Main/Exploration ); précédent : 000C24; suivant : 000C26

A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.

Auteurs : Anushka Naidoo [Afrique du Sud] ; Kogieleum Naidoo [Afrique du Sud] ; Helen Mcilleron [Afrique du Sud] ; Sabiha Essack [Afrique du Sud] ; Nesri Padayatchi [Afrique du Sud]

Source :

Journal of clinical pharmacology [ 1552-4604 ] ; 2017.

RBID : pubmed:28741299

Abstract

Moxifloxacin, an 8-methoxy quinolone, is an important drug in the treatment of multidrug-resistant tuberculosis and is being investigated in novel drug regimens with pretomanid, bedaquiline, and pyrazinamide, or rifapentine, for the treatment of drug-susceptible tuberculosis. Early results of these studies are promising. Although current evidence does not support the use of moxifloxacin in treatment-shortening regimens for drug-susceptible tuberculosis, it may be recommended in patients unable to tolerate standard first-line drug regimens or for isoniazid monoresistance. Evidence suggests that the standard 400-mg dose of moxifloxacin used in the treatment of tuberculosis may be suboptimal in some patients, leading to worse tuberculosis treatment outcomes and emergence of drug resistance. Furthermore, a drug interaction with the rifamycins results in up to 31% reduced plasma concentrations of moxifloxacin when these are combined for treatment of drug-susceptible tuberculosis, although the clinical relevance of this interaction is unclear. Moxifloxacin exhibits extensive interindividual pharmacokinetic variability. Higher doses of moxifloxacin may be needed to achieve drug exposures required for improved clinical outcomes. Further study is, however, needed to determine the safety of proposed higher doses and clinically validated targets for drug exposure to moxifloxacin associated with improved tuberculosis treatment outcomes. We discuss in this review the evidence for the use of moxifloxacin in drug-susceptible tuberculosis and explore the role of moxifloxacin pharmacokinetics, pharmacodynamics, and drug interactions with rifamycins, on tuberculosis treatment outcomes when used in first-line tuberculosis drug regimens.

DOI: 10.1002/jcph.968
PubMed: 28741299

Affiliations:

Afrique du Sud

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.</title>
<author><name sortKey="Naidoo, Anushka" sort="Naidoo, Anushka" uniqKey="Naidoo A" first="Anushka" last="Naidoo">Anushka Naidoo</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban</wicri:regionArea>
<wicri:noRegion>Durban</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Naidoo, Kogieleum" sort="Naidoo, Kogieleum" uniqKey="Naidoo K" first="Kogieleum" last="Naidoo">Kogieleum Naidoo</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban</wicri:regionArea>
<wicri:noRegion>Durban</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mcilleron, Helen" sort="Mcilleron, Helen" uniqKey="Mcilleron H" first="Helen" last="Mcilleron">Helen Mcilleron</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town</wicri:regionArea>
<wicri:noRegion>Cape Town</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Essack, Sabiha" sort="Essack, Sabiha" uniqKey="Essack S" first="Sabiha" last="Essack">Sabiha Essack</name>
<affiliation wicri:level="1"><nlm:affiliation>Antimicrobial Research Unit, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>Antimicrobial Research Unit, School of Health Sciences, University of KwaZulu-Natal, Durban</wicri:regionArea>
<wicri:noRegion>Durban</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Padayatchi, Nesri" sort="Padayatchi, Nesri" uniqKey="Padayatchi N" first="Nesri" last="Padayatchi">Nesri Padayatchi</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban</wicri:regionArea>
<wicri:noRegion>Durban</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28741299</idno>
<idno type="pmid">28741299</idno>
<idno type="doi">10.1002/jcph.968</idno>
<idno type="wicri:Area/PubMed/Corpus">000F65</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F65</idno>
<idno type="wicri:Area/PubMed/Curation">000F65</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F65</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000F65</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000F65</idno>
<idno type="wicri:Area/Ncbi/Merge">004460</idno>
<idno type="wicri:Area/Ncbi/Curation">004460</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004460</idno>
<idno type="wicri:Area/Main/Merge">000C25</idno>
<idno type="wicri:Area/Main/Curation">000C25</idno>
<idno type="wicri:Area/Main/Exploration">000C25</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.</title>
<author><name sortKey="Naidoo, Anushka" sort="Naidoo, Anushka" uniqKey="Naidoo A" first="Anushka" last="Naidoo">Anushka Naidoo</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban</wicri:regionArea>
<wicri:noRegion>Durban</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Naidoo, Kogieleum" sort="Naidoo, Kogieleum" uniqKey="Naidoo K" first="Kogieleum" last="Naidoo">Kogieleum Naidoo</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban</wicri:regionArea>
<wicri:noRegion>Durban</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mcilleron, Helen" sort="Mcilleron, Helen" uniqKey="Mcilleron H" first="Helen" last="Mcilleron">Helen Mcilleron</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town</wicri:regionArea>
<wicri:noRegion>Cape Town</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Essack, Sabiha" sort="Essack, Sabiha" uniqKey="Essack S" first="Sabiha" last="Essack">Sabiha Essack</name>
<affiliation wicri:level="1"><nlm:affiliation>Antimicrobial Research Unit, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>Antimicrobial Research Unit, School of Health Sciences, University of KwaZulu-Natal, Durban</wicri:regionArea>
<wicri:noRegion>Durban</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Padayatchi, Nesri" sort="Padayatchi, Nesri" uniqKey="Padayatchi N" first="Nesri" last="Padayatchi">Nesri Padayatchi</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban</wicri:regionArea>
<wicri:noRegion>Durban</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of clinical pharmacology</title>
<idno type="eISSN">1552-4604</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Moxifloxacin, an 8-methoxy quinolone, is an important drug in the treatment of multidrug-resistant tuberculosis and is being investigated in novel drug regimens with pretomanid, bedaquiline, and pyrazinamide, or rifapentine, for the treatment of drug-susceptible tuberculosis. Early results of these studies are promising. Although current evidence does not support the use of moxifloxacin in treatment-shortening regimens for drug-susceptible tuberculosis, it may be recommended in patients unable to tolerate standard first-line drug regimens or for isoniazid monoresistance. Evidence suggests that the standard 400-mg dose of moxifloxacin used in the treatment of tuberculosis may be suboptimal in some patients, leading to worse tuberculosis treatment outcomes and emergence of drug resistance. Furthermore, a drug interaction with the rifamycins results in up to 31% reduced plasma concentrations of moxifloxacin when these are combined for treatment of drug-susceptible tuberculosis, although the clinical relevance of this interaction is unclear. Moxifloxacin exhibits extensive interindividual pharmacokinetic variability. Higher doses of moxifloxacin may be needed to achieve drug exposures required for improved clinical outcomes. Further study is, however, needed to determine the safety of proposed higher doses and clinically validated targets for drug exposure to moxifloxacin associated with improved tuberculosis treatment outcomes. We discuss in this review the evidence for the use of moxifloxacin in drug-susceptible tuberculosis and explore the role of moxifloxacin pharmacokinetics, pharmacodynamics, and drug interactions with rifamycins, on tuberculosis treatment outcomes when used in first-line tuberculosis drug regimens.</div>
</front>
</TEI>
<affiliations><list><country><li>Afrique du Sud</li>
</country>
</list>
<tree><country name="Afrique du Sud"><noRegion><name sortKey="Naidoo, Anushka" sort="Naidoo, Anushka" uniqKey="Naidoo A" first="Anushka" last="Naidoo">Anushka Naidoo</name>
</noRegion>
<name sortKey="Essack, Sabiha" sort="Essack, Sabiha" uniqKey="Essack S" first="Sabiha" last="Essack">Sabiha Essack</name>
<name sortKey="Mcilleron, Helen" sort="Mcilleron, Helen" uniqKey="Mcilleron H" first="Helen" last="Mcilleron">Helen Mcilleron</name>
<name sortKey="Naidoo, Kogieleum" sort="Naidoo, Kogieleum" uniqKey="Naidoo K" first="Kogieleum" last="Naidoo">Kogieleum Naidoo</name>
<name sortKey="Padayatchi, Nesri" sort="Padayatchi, Nesri" uniqKey="Padayatchi N" first="Nesri" last="Padayatchi">Nesri Padayatchi</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C25 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C25 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    SidaSubSaharaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:28741299
   |texte=   A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:28741299" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a SidaSubSaharaV1

This area was generated with Dilib version V0.6.32.
Data generation: Mon Nov 13 19:31:10 2017. Site generation: Wed Mar 6 19:14:32 2024

Le SIDA en Afrique subsaharienne (serveur d'exploration)

A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.

A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Le SIDA en Afrique subsaharienne (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.